{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:00:29Z","timestamp":1778796029056,"version":"3.51.4"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In this counterpoint we critically appraise the evidence supporting therapeutic drug monitoring based on the vancomycin 24-hour area under the concentration-time curve (AUC24) for serious methicillin-resistant Staphylococcus aureus infections. We reveal methodologically weaknesses and inconsistencies in the data and suggest that, in the absence of clear and convincing evidence of benefit compared with modestly reducing trough targets, alternative strategies are more likely to result in superior safety and efficacy. These include focusing on fundamental antibiotic stewardship to limit vancomycin exposure overall, achieving earlier and more complete source control, and establishing alternative therapeutic options to vancomycin. Implementation of AUC24-based therapeutic drug monitoring will take resources away from these more promising, alternative solutions.<\/jats:p>","DOI":"10.1093\/cid\/ciaa1743","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T20:12:30Z","timestamp":1605298350000},"page":"1502-1506","source":"Crossref","is-referenced-by-count":21,"title":["Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant <i>Staphylococcus aureus<\/i> Infections?\u2014No"],"prefix":"10.1093","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1333-0378","authenticated-orcid":false,"given":"Sarah\u00a0C\u00a0J","family":"Jorgensen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Spellberg","sequence":"additional","affiliation":[{"name":"Los Angeles County + University of Southern California (LAC+USC) Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew\u00a0F","family":"Shorr","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine, Washington Hospital Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William\u00a0F","family":"Wright","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"2021070813480136000_CIT0001","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1086\/656735","article-title":"Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines","volume":"51","author":"Khan","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0002","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jama.2009.225","article-title":"Reassessment of clinical practice guidelines: go gently into that good night","volume":"301","author":"Shaneyfelt","year":"2009","journal-title":"JAMA"},{"key":"2021070813480136000_CIT0003","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0004","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van\u00a0Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"2021070813480136000_CIT0006","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/AAC.01585-08","article-title":"Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia","volume":"53","author":"Harigaya","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0007","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1128\/AAC.47.6.2018-2021.2003","article-title":"Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis","volume":"47","author":"Pavie","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0008","doi-asserted-by":"crossref","first-page":"105898","DOI":"10.1016\/j.ijantimicag.2020.105898","article-title":"Activity of pulmonary vancomycin exposures versus planktonic and biofilm isolates of methicillin-resistant Staphylococcus aureus from cystic fibrosis sputum","volume":"55","author":"Britt","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021070813480136000_CIT0009","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2021070813480136000_CIT0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/jir270","article-title":"Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations","volume":"204","author":"Holmes","year":"2011","journal-title":"J Infect Dis"},{"key":"2021070813480136000_CIT0011","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther Drug Monit"},{"key":"2021070813480136000_CIT0012","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0013","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor\u2019s new clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0014","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10096-010-1024-x","article-title":"The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia","volume":"29","author":"Shime","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2021070813480136000_CIT0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijantimicag.2013.01.009","article-title":"Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects","volume":"41","author":"Ampe","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2021070813480136000_CIT0016","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.05609-11","article-title":"Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0017","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u201coptimal\u201d cutpoints in the evaluation of prognostic factors","volume":"86","author":"Altman","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2021070813480136000_CIT0018","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/sim.2331","article-title":"Dichotomizing continuous predictors in multiple regression: a bad idea","volume":"25","author":"Royston","year":"2006","journal-title":"Stat Med"},{"key":"2021070813480136000_CIT0019","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/57.suppl_2.S4","article-title":"Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus","volume":"57(suppl 2)","author":"Moise","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"2021070813480136000_CIT0020","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0021","doi-asserted-by":"crossref","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","author":"Finch","DOI":"10.1128\/AAC.01293-17"},{"key":"2021070813480136000_CIT0022","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0023","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0024","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0025","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000343162","article-title":"Is peak concentration needed in therapeutic drug monitoring of vancomycin? a pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"58","author":"Suzuki","year":"2012","journal-title":"Chemotherapy"},{"key":"2021070813480136000_CIT0026","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC0-24 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0027","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir078","article-title":"Vancomycin: we can\u2019t get there from here","volume":"52","author":"Patel","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0028","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"2021070813480136000_CIT0029","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijid.2019.12.036","article-title":"Correlation of the vancomycin 24-h area under the concentration-time curve (AUC24) and trough serum concentration in children with severe infection: A\u00a0clinical pharmacokinetic study","volume":"92","author":"Issaranggoon\u00a0Na\u00a0Ayuthaya","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2021070813480136000_CIT0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3947\/ic.2014.46.1.21","article-title":"Underestimation of the calculated area under the concentration-time curve based on serum creatinine for vancomycin dosing","volume":"46","author":"Jin","year":"2014","journal-title":"Infect Chemother"},{"key":"2021070813480136000_CIT0031","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcp.14144","article-title":"Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals","volume":"86","author":"Smit","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2021070813480136000_CIT0032","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jcph.1498","article-title":"Optimizing vancomycin use through 2-point AUC-based therapeutic drug monitoring in Pediatric Patients","volume":"59","author":"Suchartlikitwong","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2021070813480136000_CIT0033","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/jcph.1254","article-title":"Evaluation of the effectiveness of dose individualization to achieve therapeutic vancomycin concentrations","volume":"58","author":"Abulfathi","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2021070813480136000_CIT0034","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12098-019-03162-5","article-title":"AUC- vs. trough-guided monitoring of vancomycin in infants","volume":"87","author":"Alsultan","year":"2020","journal-title":"Indian J Pediatr"},{"key":"2021070813480136000_CIT0035","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/INF.0000000000001943","article-title":"Optimizing vancomycin monitoring in pediatric patients","volume":"37","author":"Alsultan","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2021070813480136000_CIT0036","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0000000000000622","article-title":"Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections","volume":"41","author":"Clark","year":"2019","journal-title":"Ther Drug Monit"},{"key":"2021070813480136000_CIT0037","first-page":"801","article-title":"Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?","volume":"72","author":"De\u00a0Cock","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021070813480136000_CIT0038","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13318-019-00568-6","article-title":"Clinical pharmacokinetics of vancomycin in critically ill children","volume":"44","author":"Sridharan","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2021070813480136000_CIT0039","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01647-17","article-title":"Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates","volume":"62","author":"Tseng","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.diagmicrobio.2018.06.022","article-title":"Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population","volume":"92","author":"Turner","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021070813480136000_CIT0041","doi-asserted-by":"crossref","first-page":"1286. e1","DOI":"10.1016\/j.cmi.2019.02.029","article-title":"Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting","volume":"25","author":"Broeker","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2021070813480136000_CIT0042","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.semnuclmed.2007.09.003","article-title":"Monitoring renal function and limitations of renal function tests","volume":"38","author":"Prigent","year":"2008","journal-title":"Semin Nucl Med"},{"key":"2021070813480136000_CIT0043","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00005373-200208000-00013","article-title":"Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients","volume":"53","author":"Cherry","year":"2002","journal-title":"J Trauma"},{"key":"2021070813480136000_CIT0044","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: How well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front Pharmacol"},{"key":"2021070813480136000_CIT0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: a review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2021070813480136000_CIT0046","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.clinthera.2013.05.008","article-title":"A stewardship program\u2019s retrospective evaluation of vancomycin AUC24\/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"35","author":"Gawronski","year":"2013","journal-title":"Clin Ther"},{"key":"2021070813480136000_CIT0047","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0048","author":"U.S. Food and Drug Administration (2019). Clinical Decision Support Software. Draft Guidance for Industry and Food and Drug Administration Staff. Rockville, MD: U.S. Food Drug Administration."},{"key":"2021070813480136000_CIT0049","volume-title":"Government of Canada. Draft Guidance Document - Software as a Medical Device (SaMD):","author":"Health Canada"},{"key":"2021070813480136000_CIT0050","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480136000_CIT0051","article-title":"Personalised dosing of vancomycin: A\u00a0prospective and retrospective comparative quasi-experimental study","author":"Vali","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2021070813480136000_CIT0052","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an Academic Medical Center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2021070813480136000_CIT0053","article-title":"Vancomycin advanced therapeutic drug monitoring: An exercise in futility or virtuous endeavor to improve drug efficacy and safety?","author":"Dilworth","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0054","article-title":"Heaping the pelion of vancomycin on the Ossa of MRSA: Back to basics in clinical care and guidelines","author":"Wright","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021070813480136000_CIT0055","first-page":"194","article-title":"Vital signs: improving antibiotic use among hospitalized patients","volume":"63","author":"Fridkin","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021070813480136000_CIT0056","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jinf.2015.09.037","article-title":"Infectious disease consultation for Staphylococcus aureus bacteremia-A\u00a0systematic review and meta-analysis","volume":"72","author":"Vogel","year":"2016","journal-title":"J Infect"},{"key":"2021070813480136000_CIT0057","doi-asserted-by":"crossref","first-page":"ofw210","DOI":"10.1093\/ofid\/ofw210","article-title":"How to Pitch an Antibiotic stewardship program to the hospital C-Suite","volume":"3","author":"Spellberg","year":"2016","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1743\/36645944\/ciaa1743.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/9\/1502\/37796106\/ciaa1743.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/9\/1502\/37796106\/ciaa1743.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T22:31:07Z","timestamp":1625783467000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/9\/1502\/6178883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,3,19]]},"published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1743","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,3,19]]}}}